Mammalian cells express two homologs of the SWI2 subunit of the SWI/SNF chromatin-remodeling complex called BRG1 and BRM. Whether the SWI/SNF complexes formed by these two subunits perform identical or dierent functions remains an important question. In this report, we show concomitant downregulation of BRG1 and BRM in six human tumor cell lines. This down-regulation occurs at the level of mRNA abundance. We tested whether BRM could aect aberrant cellular functions attributed to BRG1 in tumor cell lines. By transient transfection, we found that BRM can restore RB-mediated cell cycle arrest, induce expression of CD44 protein and suppress Cyclin A expression. Therefore, BRM may be consistently downregulated with BRG1 during neoplastic progression because they share some redundant functions. However, assorted tissues from BRM null/BRG1-positive mice lack CD44 expression, suggesting that BRM-containing SWI/SNF complexes regulate expression of this gene under physiological conditions. Our studies further de®ne the mechanism by which chromatin-remodeling complexes participate in RB-mediated cell cycle arrest and provide additional novel evidence that the functions of SWI/SNF complexes containing BRG1 or BRM are not completely interchangeable.
Introduction
Chromatin, a highly condensed and dynamic structure, must be temporally rearranged so that speci®c genes can be expressed or repressed. The SWI/SNF complex, conserved in yeast, drosophila and mammals, represents one mechanism to carry out this function (Kingston and Narlikar, 1999; Wu et al., 1998) . The SWI/SNF complex was ®rst de®ned in yeast that had defects in mating type switching and sugar non-fermenting (Carlson and Laurent, 1994; Winston and Carlson, 1992) . The genes responsible for this mutant phenotype SWI2/SNF2, SWI3, SWP73 and SNF5, form a multimeric complex that promotes gene expression by remodeling chromatin (Peterson et al., 1994) . Mutations or loss of expression of any of these proteins causes the complex to be nonfunctional and results in similar but not identical phenotypes (Carlson and Laurent, 1994; Laurent et al., 1991 Laurent et al., , 1993 . These mutant phenotypes can be partially reversed by secondary mutation in histones or other nuclear proteins (Hirschhorn et al., 1992; Kingston et al., 1996; Kruger et al., 1995; Santisteban et al., 2000; Winston and Carlson, 1992) . The active SWI/SNF complex regulates gene expression by modifying nucleosomes through an incompletely characterized mechanism that is both ATP and DNA dependent (Imbalzano et al., 1994; Krebs and Peterson, 2000; Peterson and Tamkun, 1995; Schnitzler et al., 1998a,b) The mammalian SWI/SNF complexes contain either of two ATPase subunits, BRM (brahma) or BRG1 (Brahma Related Gene), plus an additional 9 ± 12 proteins called BRM/BRG1 Associated Factors (BAFs) (Wang et al., 1996) . In mammalian cells, the SWI/SNF complex regulates expression of a number of genes including CD44, HSP70, c-FOS, Cyclin A and MyoD genes (de La Serna et al., 2000 Murphy et al., 1999; Strobeck et al., 2001 : Zhang et al., 2000 . It is believed that the complex is targeted to promoters by transcription factors and histone acetylation (Lee et al., 1999b; Wole and Guschin, 2000; Wu et al., 2000) . A direct regulatory role of the SWI/SNF complex has also been demonstrated with the b-hemoglobin gene locus and certain myeloid lineage speci®c genes (Armstrong et al., 1998; Kowenz-Leutz and Leutz, 1999; Lee et al., 1999a) . SWI/SNF complexes also bind to and potentiate the functions of the estrogen, glucocorticoid and retinoic acid receptors (Chiba et al., 1994; Khavari et al., 1993; Muchardt and Yaniv, 1993; Singh et al., 1995; Wallberg et al., 2000) . While the number of genes in mammalian cells dependent on SWI/SNF function remains unknown, the SWI/SNF complex is estimated to regulate expression of approximately 5% of genes in yeast .
With its pivotal role in regulating the activity of multiple transcription factors and signaling pathways, one would predict an association of altered SWI/SNF function with disease. This notion has proven correct in the case of neoplasia. The SWI/SNF subunit, SNF5/ INI1, behaves like a bona ®de tumor suppressor gene: mutations in this gene occur in the majority of sporadic human rhabdoid tumors with germline mutations resulting in the development of familial rhabdoid tumors (Biegel et al., 2000a,b; DeCristofaro et al., 1999; Sevenet et al., 1999a,b; Versteege et al., 1998) . Several reports have also shown BRG1 mutations and/or loss of protein in approximately 10% of human cancer cell lines Wong et al., 2000) . Previous studies provide a potential mechanism of action for BRG1 loss in human cancers by its demonstrated binding to the retinoblastoma (RB) tumor suppressor protein and its requirement for cell cycle inhibition by the RB protein (Strober et al., 1996; Knudsen et al., 1999; Strobeck et al., 2000; Zhang et al., 2000) . These ®ndings suggest that BRG1 loss represents an alternative pathway for inactivation of RB tumor suppressor activity. In contrast mutations in the other SWI2 homolog, BRM, have not been reported although it also can bind to RB (Strober et al., 1996) .
Animal studies have also provided evidence for a role of SWI/SNF loss in the development of neoplasia. SNF5/INI1 heterozygous mice develop tumors with features of human rhabdoid tumors (Guidi et al., 2001; Klochendler-Yeivin et al., 2000; Roberts et al., 2000) . Bultman et al. (2000) have shown that BRG1 +/7 mice develop subcutaneous glandular tumors that resemble breast adenocarcinomas. In contrast, the BRM 7/7 mice develop normally but are 10 ± 15% heavier than their heterozygous littermates, and do not develop tumors (Reyes et al., 1998) . These ®ndings indicate that while both BRG1 and BRM play roles in growth control, only BRG1 loss may lead to the development of cancer. These phenotypic dierences between BRG1 versus BRM loss suggest that their cellular functions are not equivalent.
Our investigations have shown that concomitant, reduced expression of both BRM and BRG1 represents the most frequent alteration of the SWI/SNF complex in human cancers, occurring in approximately 10% of human tumor cell lines analysed (DeCristofaro and Reisman unpublished observations). Prior to these investigations, three human cell lines (SW13, C33A and Panc-1) were known to have severely reduced expression of BRG1 and BRM (Strobeck et al., 2000) . Two of these cell lines are also de®cient in BRM as well as BRG1 (Strobeck et al., 2001; Wong et al., 2000) . In this report, we uncovered three additional cell lines, NCI ± H522, NCI ± H125 and NCI ± H1573, which are also de®cient in both BRG1 and BRM protein expression. Transient transfection experiments show that a cross-regulating mechanism is not present but rather that both genes are down-regulated at the level of their mRNAs. This tandem down-regulation of the SWI/SNF ATPases BRG1 and BRM suggests that redundancy may exist between their functions and that loss of both genes provides a growth advantage. In support of this concept, we demonstrate that introduction of BRM, like BRG1, in human cell lines can restore RB-mediated repression of Cyclin A, RBmediated cell cycle arrest and expression of the cell surface glycoprotein CD44. However, BRM-knockout mice do not show CD44 expression, despite the presence of high levels of BRG1. These ®ndings suggest that while the functions of these proteins overlap, expression levels, developmental stage and tissue restricted expression signi®cantly in¯uence their activities.
Results

Down-regulation of the SWI/SNF ATPase subunits BRG1 and BRM in adenocarcinoma cell lines
While investigating the expression pattern of the SWI/ SNF complex members in 40 human cancer cell lines , we found that BRG1 and BRM were the most frequently down-regulated members of the SWI/SNF complex. This downregulation of expression was found in 3/40 cell lines (*10%). In addition to SW13, Panc-1 and C33A, we now report three additional cell lines, NCI ± H522, NCI ± H125 and NCI ± H1573, which show greatly decreased levels of BRM and BRG1 protein ( Figure  1 ). Prior to our investigations, Reyes et al. (1997) showed that dierent pools of the SWI/SNF complex exist that could be progressively eluted under sequentially more stringent conditions. This high anity of the SWI/SNF proteins for chromatin has been attributed to the high mobility protein (HMG) motifs contained in several of the BAF proteins (Bourachot et al., 1999; Quinn et al., 1996; Wang et al., 1998) . Although dierent extraction methods can elute the SWI/SNF complex, only the most stringent methods such as 8 M urea can elute the majority of the tightly bound fractions. To insure that the BAF proteins were being eciently extracted, we used the urea extraction method described by Reyes et al. (1997) which solubilizes almost all cytoplasmic and nuclear proteins (Reyes et al., 1997) . While C33A, Panc-1 H125 and H1573 express reduced levels of both BRG1 and BRM proteins, H522 and SW13 do not express detectable levels of either protein (Figure 1 ). Using an NP40 extraction method, we selectively isolated the cytosolic proteins and found that BAF proteins were not detectable in this fraction (data not shown). This indicates that the urea method employed re¯ects the actual BAF protein array within the nucleus. There-fore, loss of these proteins is not occurring because of defects in nuclear localization. Based on this observation, we hypothesized that down-regulation of BRG1 and BRM may be concordant yet independent events, or that these proteins might cross regulate each other's expression.
Decreased expression of BRG1 and BRM proteins is associated with reduced mRNA levels To further investigate why BRG1 and BRM are coordinately down regulated in these six cell lines, Northern blots were performed with polyA + mRNA. In general, we found that cell lines with little or no detectable BRG1 and BRM protein expression gave similar results by Northern blotting (Figure 2a ). The C33A cell line appears to be the exception to this ®nding. The BRG1 mRNA level of C33A is higher than the other cells with diminished BRG1 protein expression. Despite this ®nding, the BRG1 protein level in this cell line is low, leading to resistance to RBmediated growth arrest (Strobeck et al., 2000; Zhang et al., 2000) . Our results suggest that a post-transcriptional process accounts for the reduced BRG1 protein expression in the C33A cell line.
While we could not detect BRM mRNA expression in the H522 and SW13 cell lines by Northern blotting, we could demonstrate expression by nonquantitative RT ± PCR using a high number of cycles (*35) (Figure 2b ). The BRG1 (*1.2 kb) and BRM (*1.0 kb) PCR products are attributed to low levels of mRNA present in these cells rather than contaminating DNA for two reasons. The PCR primers cross multiple exons and would generate a 45 kb product if a DNA template was present. Second, we did not detect the *1.2 kb BRG1 or *1.0 kb BRM products when we used genomic DNA as a template (Figure 2b , lane 1). Therefore, we could ®nd transcription of both BRG1 and BRM in all cell lines by at least one method, although at least two cell lines (H522 and SW13) lacked detectable protein. This result raised the possibility that each cell line possessed a small fraction of cells expressing wild-type levels of BRG1/BRM protein.
To determine if this held true, we used immunohistochemistry to determine BRG1 and BRM protein expression in individual cells. Immunostaining of the C33A SW13 and H522 cell lines showed no expression of BRG1/BRM protein as compared to HeLa cells, a positive control ( Figure 3 ). These results indicate that very low expression of BRG1 and BRM in these cell lines occurs in a homogenous manner, and is not due to clonal variation.
BRG1 and BRM do not cross-regulate each other's expression
Because BRG1 and BRM are concordantly downregulated in human cell lines, we hypothesized that BRG1 and BRM may cross-regulate each other's expression. To determine if exogenous expression of BRG1 could induce BRM expression or vice versa, transient transfection experiments were conducted with the H522 and SW13 cell lines, which express barely detectable levels of BRG1 and BRM proteins ( Figure  1a ). We initially determined by Western blot analysis that exogenous expression of BRM did not lead to reexpression of endogenous BRG1 (Figure 4a ). In contrast, it appeared that exogenous expression of BRG1 led to the re-appearance of endogenous BRM protein using the Transduction Laboratories monoclonal antibody ( Figure 4a , third row). However, Northern blot analysis did not con®rm this ®nding ( Figure 4b ). We had also seen dierences in BRM expression in Figure 1a using this antibody compared to our well-characterized anity-puri®ed anti-BRM antibody (Reyes et al., 1998) (row 2 vs row 3). To resolve this con¯ict, we re-probed the same Western blots using a dierent anti-BRM antibody from Santa Cruz Laboratories. We did not detect BRM expression after transient transfection of the BRG1 expression vector, consistent with the Northern blot data. Therefore, it appears that the monoclonal antibody developed by Transduction Laboratories recognizes both BRG1 and BRM. In summary, our results indicate that concomitant down-regulation of BRG1 and BRM does not account for their simultaneous loss in these tumor cell lines. Because six dierent human tumor cell lines showed concordant loss of BRM and BRG1, we examined whether BRM could regulate expression of two other genes, Cyclin A and CD44, previously identi®ed as regulated by BRG1 (Strobeck et al., 2001) . The latter gene codes for the CD44 protein, an important marker of metastasis in a variety of human tumors (Herrlich et al., 1998; Sherman et al., 1996) . We transfected the H522 cell line with BRG1, a positive control, or BRM. We found that in addition to BRG1, BRM could restore CD44 expression (Figure 4a ). To further investigate if BRM could act in similar capacity as BRG1, we examined whether BRM could cooperate with RB to repress Cyclin A. To test this, we transfected a human Cyclin A-promoter reporter vector with either PSM ± RB, a constitutively active form of RB, or PSM ± RB plus BRM. Co-transfection of BRM and PSM ± RB caused an approximately threefold reduction in Cyclin A reporter activity compared to PSM ± RB alone (Figure 5a ). Consistent with this observation, we found that transfection of BRM alone did not alter Cyclin A expression, while co-transfection of BRM and PSM ± RB inhibited Cyclin A protein levels, after normalization to Cdk4 (Figure 5b ). These ®ndings indicate that under transient transfection conditions, BRG1 and BRM can independently regulate CD44 and Cyclin A gene expression. Initial investigations have shown that BRG1/BRM de®cient cell lines are resistant to RB-mediated cell cycle arrest (Strobeck et al., 2000; Zhang et al., 2000) . However, re-expression of BRG1 with PSM ± RB restores the ability of PSM ± RB to inhibit cell cycle progression. These results suggest that BRG1 is critical for transducing RB-inhibitory signals. Since both BRG1 and BRM have the ability to bind RB, we postulated that BRM might also restore RB-mediated growth inhibition. To this end, we introduced either BRM or BRG1 alone or in combination with PSM ± RB or p16 ink4a into the H522 and SW13 cell lines. Figure 6 shows that neither SW13 nor the H522 cell line are arrested by expression of the PSM ± RB or p16 ink4a proteins as measured by BrdU incorporation. However, co-transfection of BRM with either PSM ± RB or p16 ink4a restored cell cycle arrest as eciently as co-transfection with BRG1. We analysed data from ®ve independent experiments using the Exact Kruskal ± Wallis test for multi-sample data, and found that these results were statistically signi®cant (see legend Figure   Figure 3 BRG1 expression in human tumor cell lines by immunohistochemistry. HeLa (BRG1-positive control), SW13, C33A and H522 were each placed in a ®brinous clot, formalin ®xed and then embedded in paran blocks. Immunohistochemistry for BRG1 and BRM/BRG1 expression was then preformed as outlined in Material and methods. Only the HeLa cells showed strong nuclear staining with the BRG1 antibody or the BRG1/BRM antibody, which detects both BRG1 and BRM. In the SW13, C33A and H522 cells neither BRG1 nor BRM nuclear staining was detected 6). These experiments show that re-expression of BRM can restore RB-mediated cell cycle arrest as eectively as BRG1 under transient transfection conditions.
Loss of BRM alone is sufficient to cause loss of CD44 expression
While these studies suggest that BRG1 and BRM function in a redundant fashion, they do not address the potential nuances associated with endogenous expression. Therefore, to get a representation of the normal functions of these proteins under physiological conditions, we examined CD44 protein expression as a function of BRG1 and BRM in mouse tissues by immunohistochemistry. Using wild-type BRM (BRM +/+ ), heterozygous BRM (BRM +/7 ) or homozygous null BRM (BRM 7/7 ) genetically altered mice (Reyes et al., 1998) , we harvested multiple organs and stained for CD44 expression. In both the BRM +/+ and BRM +/7 mice, CD44 was detected in lung tissue (Figure 7) . However, BRM 7/7 mice did not show expression of the CD44 protein in lungs (Figure 7) . Similar results were observed with other tissues including gut epithelium, liver and brain (data not shown). The absence of BRM was con®rmed in these three genotypes by Western blotting of brain tissue from each BRM genotype. Consistent with a prior report of Reyes et al. (1998) , we saw upregulation of BRG1 when BRM was not expressed (data not shown). This result shows that under physiological conditions, loss of BRM alone, even in the presence of higher than normal levels of BRG1, can ablate CD44 expression.
Discussion
Multiple studies have implicated altered SWI/SNF complex function in the development of cancer by demonstrating the loss of the BRG1, BRM, BAF57 or hSNF5 subunits in dierent subsets of tumors Rosty et al., 1998; Sevenet et al., 1999a,b; Versteege et al., 1998; Vignali et al., 2000; Wang et al., 1996) . By screening a large number of cell lines, we, as well as Wong et al. (2000) , found a correlation between loss of BRG1 and the related SWI2 homolog BRM. Based on these observations, we hypothesized that either BRG1 regulated the expression of BRM or vice versa or that both genes were independently down-regulated. Our experiments show that cross-regulation does not occur. Therefore, other mechanisms must account for the dual loss, including independent inactivation of each gene through mutation or loss of a transcription factor(s) that regulates expression of both genes.
The mechanism(s) behind the loss of BRG1 and BRM expression in the tumor lines characterized in this report remains unknown. While Southern blot analyses revealed no alterations of the BRG1 gene (data not shown), we observed low or undetectable expression of BRG1 mRNA. These cell lines may Figure 6 BRM can restore RB-mediated cell cycle arrest in adenocarcinoma cell lines with diminished BRG1 expression. Three micrograms of BRM or BRG1 plasmid DNA was transiently transfected in the H522 and SW13 cell lines with 3 mg of empty vector, with 3 mg of p16 ink4a or 3 mg of PSM ± RB plasmid. Histone 2B linked GFP, 0.5 mg per transfection, was used to identify recipient cells. Cells were incubated for 48 h, pulsed for 24 h with BrdU then ®xed and stained with an anti-BrdU antibody. Per cent proliferation was calculated by the ratio of BrdU labeled cells to total number of transfected cells and normalized to the ratio observed after transfection with empty vector alone. To determine if these observed eects were statistically signi®cant, we pooled data from ®ve and three independent experiments with the SW13 and H522 cell lines, respectively. Using the Exact Kruskal ± Wallis test for multi-sample data, we found the groups of, p16 ink4a +BRG1 and p16 ink4a +BRM as well as RB, RB+BRG1 and RB+BRM were statistically signi®cant with P values of 0.0028 and 0.0214. Pair-wise analysis showed that p16ink4a or RB-mediated growth inhibition was not dierent between the BRG1 and BRM groups in the H522 cell line (P values of 0.1152 and 0.4 respectively) and in the SW13 cell line (P values of 1.0 and 1.0 respectively) a b Figure 5 Re-expression of BRM restores RB-mediated down-regulation of Cyclin A expression. (a) SW13 cells were transfected with 0.5 mg of the Cyclin A promoter reporter plasmid 7608 Luc, 1 mg of CMV-gal, and the following expression plasmids: BRM (1.6 mg), PSM ± RB (1.6 mg) or PSM ± RB (1.6 mg)+BRM (1.6 mg) as indicated. All transfections were brought to 4 mg total plasmid DNA using parental vector (CMVNeoBam). Data shown are from two independent experiments and were normalized to û-gal activity for transfection eciency. (b) SW13 cells were transfected with (1 mg) pBabe-Puro along with (15 mg) CMVNeoBam (lane 1), (7.5 mg) PSM ± RB (lane 2), (7.5 mg) pCG ± BRM (lane 3) and (7.5 mg) PSM ± RB+(7.5 mg) pCG ± BRM (lane 4). All transfections were brought to 16 mg total plasmid DNA using parental vector (CMVNeoBam) Following puromycin selection, equal total protein was resolved by SDS ± PAGE, and then immunoblotted for Cyclin A and Cdk4 possess defects in transcription such as promoter mutations or methylation as observed with the p16 ink4a , VHL and RB genes (Baylin and Herman, 2000) . However, mutations that alter the structure of proteins may also lead to the absence of detectable protein in tumor cell lines (Wong et al., 2000) . We observed that all cell lines (except C33A) express low levels of BRG1 mRNA as determined by Northern blot. These data cannot distinguish whether this low expression arises from reduced transcription and/or increased mRNA turnover. However, we could easily detect mRNA expression in the cell lines by RT ± PCR. These ®ndings suggest that a very low amount of BRG1 protein may be necessary for viability, consistent with the lethality observed in mouse knock-out and somatic cell knockout studies (Bultman et al., 2000; Sumi-Ichinose et al., 1997) . Whether BRM mutations exist in these cell lines requires further study. The sequence analysis of the BRM gene will present a formidable task due to its large number of exons (434) 2000) and Xue et al. (2000) found two basic types of SWI/SNF complexes that they named BAF and PBAF. The BAF complex possesses BAF250 and may contain either BRG1 or BRM. The PBAF contains BAF180 and BRG1, but not BRM. The BAF complex participates in glucocorticoid signaling, while the PBAF complex localizes to the kinetochores during mitosis and may regulate cell division. Sif et al. (2001) also found two BRG1-containing complexes as well as one BRM-possessing complex by a similar puri®cation scheme. They also demonstrated functional dierences among these complexes using in vitro biochemical assays. Furthermore, Bultman et al. (2000) have shown total loss of BRG1 expression in mice is a lethal event. However, BRM 7/7 mice are viable but are 10 ± 15% heavier than their heterozygous littermates (Reyes et al., 1998) . The loss of each gene also aects tumor development dierently. While BRG1 +/7 mice develop subcutaneous glandular tumors that resemble breast adenocarcinomas, tumors do not appear in the homozygous BRM knockout mice (Bultman et al., 2000; Reyes et al., 1998) .
Our results suggest that, even though BRM and BRG1 are contained in dierent SWI/SNF complexes, either protein can participate in RB-mediated cell cycle arrest or CD44 expression under certain circumstances. This mechanism of substitution might be bene®cial when one gene is lost, thereby allowing the other gene to compensate. Consistent with this idea, the BRG1-de®cient OV-1063 cell line shows 2 ± 3-fold higher levels of BRM (Muchardt and Yaniv, 2001) . Similarly, tissue from BRM null mice shows 2 ± 3-fold upregulation of BRG1 (Reyes et al., 1998) . These facts may explain why both BRG1 and BRM are concomitantly lost in many human tumor cell lines. In order to achieve a complete loss of SWI/SNF complex activity, tumor cells must decrease expression of both SWI2 homologs. However, in BRM null mice, CD44 expression was absent despite the continued expression of BRG1. Several possible mechanisms could account for these observations including dierences in cell type, developmental stage and protein levels. Recently, Muchardt and Yaniv (2001) have found several human cell lines that express BRG1 but not BRM. However, it is not known if BRG1 is functional within these cell lines (i.e. if they undergo RB growth arrest).
The only tumors observed in the BRG1 +/7 mice seemed to arise from glandular epithelium. Consistent with this observation, all six BRG1/BRM-de®cient cell lines characterized in this report as well as 5/16 cell lines reported by Wong et al. (2000) originate from human adenocarcinomas. The mechanism for this apparent preferential association of BRG1/BRM loss with the development of adenocarcinomas remains unknown. However, this restriction may arise from the type of transcription factors associated with SWI/SNF complex activity. For example, several reports have demonstrated an association between BRCA1 and BRG1 (Bochar et al., 2000; Neish et al., 1998) . This interaction aects p53-mediated transcription and RNA Polymerase II activity. Loss of BRCA1 function also leads to a speci®c set of tumors classi®ed as adenocarcinomas (Iau et al., 2001) . Unlike RB, it is not known if BRM can also interact with BRCA1. Therefore, further investigation of the potential BRCA1-SWI/SNF interactions may provide some insight into this apparent preferential association of BRG1 mutations with adenocarcinomas.
Multiple reports by Versteege, Sevenet, our laboratory and others have shown that another member of the SWI/SNF complex, SNF5/INI1/BAF47, frequently undergoes bialleleic deletion in pediatric rhabdoid tumors and in several types of CNS tumors (DeCristofaro et al., 1999; Rosty et al., 1998; Sevenet et al., 1999a,b; Versteege et al., 1998; Vignali et al., 2000) . Like BRG1-de®cient mice, BAF47/INI1 knockout animals display embryonic lethality. However, heterozygous mice develop only rhabdoid-like tumors (Klochendler-Yeivin et al., 2000; Roberts et al., 2000) . The dierence in types of tumors seen in these two dierent knockout mice raises important questions about the contributions of other complex members to normal SWI/SNF function. The strong association between tumor development and loss of two dierent SWI/SNF complex members emphasizes the importance of further studies on the potential role of other SWI/SNF complex members in human cancers. Whether BRM-containing SWI/SNF complexes control expression of a subset of genes regulated by the BRG1 complexes, or whether they regulate an overlapping group, remains an intriguing question.
Materials and methods
Cell lines
All cell lines were obtained from the ATCC and grown in RPMI 1640 plus 10% PBS (Sigma). Cell lines were grown at 378C, with 5% CO 2 and routinely passaged at 1 : 10 ± 1 : 20 dilution twice per week.
Protein isolation
Urea extracts were prepared as previously described in . Brie¯y, cells were grown on 100 mm plates and harvested at 70 ± 80% con¯uency. Cells were trypsinized and washed in PBS then transferred to 1.6 ml microcentrifuge tubes. Cells were then pelleted by brie¯y centrifuging and the PBS was then aspirated. Prior to the addition of the urea buer, the cells were completely resuspended in the residual PBS. Three to four pellet volumes of ice-cold urea buer (90% 8.8 M urea, 2% 5 M NaH 2 PO 4 , 8% 1 M Tris pH 8.0 were added, incubated for 30 min at 48C and then centrifuged at 15 000 r.p.m. for 30 min. The supernatant was collected and stored at 7708C.
Western blotting
Immunoblotting for BAFs All samples were assayed by the Bradford assay Kit (Bio Rad). Thirty mg of urea lysate were mixed with 6 6Lamelli loading buer and boiled for 5 min prior to loading on 7.5% PAGE precast gel (Fisher). Samples Immunoblotting for Cyclin A Approximately 2610 6 SW13 cells were plated in 10 cm dishes 24 h before transfection. Transfected SW13 cells were selected post-transfection with 2.5 mg/ml puromycin (Sigma) for 48 h and then harvested for protein analysis. For immunoblotting, cells were trypsinized and then washed twice with PBS. The cell pellets were resuspended in RIPA buer containing protease inhibitors (1 ul (10 mg/ml) phenanthroline, 10 ul (2 mg/ml) aprotinin, 10 ul (2 mg/ml) leupeptin, and 1 mM phenylmethylsulfonyl uoride) and phosphatase inhibitors (10 mM sodium¯uoride, 0.1 mM sodium vanadate, and 60 mM û-glycerophosphate) for 15 min on ice. The lysates were brie¯y sonicated and centrifuged at 20 000 g for 10 min at 48C. The lysates were fractionated by SDS-polyacrylamide gel electrophoresis and then transferred onto Immobilon P (Millipore). The membranes were then incubated with primary polyclonal antibodies: anti-Cyclin A (clone H-432, Santa Cruz) and anti-Cdk4 (clone H-22, Santa Cruz). The blots were then incubated with horseradish peroxidase conjugated goat anti-rabbit IgG (Biorad) for 1 h at room temperature. The antibody-antigen complex was detected by enhanced chemiluminescence procedure (ECL, Amersham-Pharmacia Biotech).
Northern blotting
PolyA
+ mRNA was collected from cells grown to 70% con¯uency on 100 mm dishes using the Qiagen Oligotex Direct kit according to the manufacturer's instructions. Total RNA was collected by using a trizol-based protocol (Gibco-BRL). Two mg of polyA + mRNA or 10 mg of total RNA was loaded per lane in a 2.2 M formaldehyde gel, separated by electrophoresis at 40 volts for 4 h, transferred to a nylon membrane overnight and cross-linked using 150 joules UV from a GS Gene Linker (BioRad). The membranes were hybridized with Perfecthyb Plus (Sigma). The BRG1 and BRM cDNA were compared using the BLAST program at NCBI and non-homologous regions were identi®ed in the ®ve prime end of each of these genes. To generate unique DNA probes by PCR, the BRM probe was generated by PCR using the primers (5-GGAATGGATGGTTTCCCTGT and 3-CCACCAGCTCTTGTGCTCAG) and the BRG1 probe was generated using the primers 5-CACTCCCAAGGTTAC-CCCTCG and 3-ATTCGCCATGGGTCCTTCAG. Probes were prepared by a random priming kit (Promega) according to the manufacturer's instructions, with resultant speci®c activity of 41610 9 counts mg.
RT ± PCR of BRG1 and BRM mRNA RT ± PCR was conducted using the Qiagen HotStart Kit. A working solution was prepared according to the manufacturer's instructions and aliquoted. Either 100 ng of polyA + mRNA, 500 ng of genomic Jurkat DNA or 1 ng of the cDNA was added to each aliquot and used as the template. Primers were chosen to span more than two exons; BRG1: 5' primer was CATCATCGTGCCTCTCTCAAC and the 3' primer was ACACGCACCTCGTTCTGCTG which yielded a *1.2 kb product. The BRM 5' primer was CCAGTAGG-CAGGAAACCGAAG and the 3' primer was GGCTTGCA-TATGGCGATACA which yielded a *1.0 kb product. The reverse transcriptase reaction was run at 508C for 30 min followed by 35 cycles where the annealing temperature was 608C for 1 min, extension temperature was 728C for 90 s and the melting temperature was 948C for 1 min. Twenty microliters of each PCR product was then separated on a 1% gel by electrophoresis then stained with ethidium bromide and photographed under UV illumination.
Transient transfections
Cells were grown to 60 ± 70% con¯uence in 100 mM plate with RPMI media with 10% FBS without antibiotics. Transfections were carried out using Lipofectamine 2000 according to the manufacturer's instructions. Either 20 mg pBJ5 ± BRG1B, 20 mg of pCG ± BRM (a gift from Dr Weidong Wang) or pBJ5 ± BRG1A (Reisman-unpublished) was added to each plate and cultured for 48 h prior to harvesting. Protein lysates were harvested by the 8 M urea method described in Protein Isolation.
Cyclin A reporter assays
Approximately 5610 5 SW13 cells were plated into 6 cm dishes. Twenty-four hours later, the cells were transfected (as indicated) with 8 mg of total plasmid DNA. Seventy-two hours post-transfection the cells were harvested. The Luciferase Assay System (Promega) was used to determine the luciferase activity of the transfected cells. Transfection eciency was determined by û-galactosidase activity and the relative luciferase activity shown was determined after its normalization to b-galactosidase activity. The data re¯ect the average of at least three independent experiments.
BrdU incorporation assay
Cells were transferred to 6-well plates and grown on glasscovered slips (Corning) prior to transfection. Transient transfections were conducted using 6 ul of Lipofectamine 2000 per well. For single gene transfers, 3 mg of plasmid DNA and 3 mg of empty vector were used. For dual gene transfers, 3 mg of each plasmid was used. In addition, 0.5 mg of GFP linked to histone2B (a gift from Dr Georey Wahl) was added to each transfection to identify transfected cells during¯uorescent microscopy. Cells were cultured for 36 h then Bromodeoxyuridine (BrdU) Amersham-Pharmacia Biotech was added at 3 mg/ml {1 : 1000 dilution} for 24 h. Cells were then ®xed with 90% ice-cold ethanol and 5% glacial acetic acid for 30 min. Cells were stained for BrdU incorporation using anti-BrdU antibody (Amersham-Pharmacia Biotech) for 60 min at RT, washed 26 with PBS, and incubated with an AlexaFluor anti-mouse IgG. Transfected cells as identi®ed by the GFP¯uorescence were then scored for BrdU incorporation by¯uorescent microscopy.
BRG1 and CD44 immunohistochemistry
Five micron sections were cut and mounted onto Probe On Plus slides (Fisher Scienti®c). Following deparanization in xylene, slides were rehydrated through a graded series of alcohol and placed in running water. Antigen retrieval was done in citrate buer. Following cooling and rinsing in PBS, endogenous peroxidase was quenched and slides were incubated in a 1 : 50 dilution of rat anti-mouse CD 44 (Hermes 3) or mouse anti-human BRG1 monoclonal antibody (a kind gift from P Chambon, Pasteur Institute) for 30 m at 378C (Sumi-Ichinose et al., 1997) . Detection was performed using the InnoGenex animal kit for 5 min at 378C each in both the secondary antibody and the label. The antibody/label complex was then visualized with 3,3' -diaminobenzidine tetrahydrochloride (DAB) and the slides were then counterstained in Harris' hematoxylin (Dako), dehydrated, cleared and mounted.
